Search Results
Sep 09, 2026, 05:00 ET Terapia de edición bases con tBE logra remisión clínica duradera en drepanocitosis y β-talasemia en varios fondos genét
chinos con talasemia dependiente de transfusiones (TDT), un nuevo estudio confirma que la tBE es igualmente segura y eficaz para pacientes africanos con SCD y pacientes con TDT del sur y sureste de Asia.SHANGHAI, 9 de septiembre
More news about: CorrectSequence Therapeutics
Sep 08, 2026, 12:52 ET Cell Stem Cell: Die tBE-vermittelte Base-Editing-Therapie erzielt bei unterschiedlichen genetischen Hintergründen eine dauerhafte klinische Remission bei Sichelzellkrankheit und β-Thalassämie
bei chinesischen TDT-Patienten eine 100-prozentige Transfusionsunabhängigkeit erreicht wurde, bestätigt eine neue Studie, dass tBE für afrikanische SCD-Patienten sowie für TDT-Patienten aus Süd- und Südostasien ebenso sicher und wirksam ist.SHANGHAI,
More news about: CorrectSequence Therapeutics
Sep 08, 2026, 10:41 ET Cell Stem Cell : la thérapie d'édition de bases médiée par tBE permet d'obtenir une rémission clinique durable dans la drépanocytose et la bêta-thalassémie, quel que soit le profil génétique des patients
traitement à quatre patients supplémentaires originaires du Nigeria, du Laos, de Malaisie et du Pakistan dont un est atteint de drépanocytose (SCD) et trois sont atteints de TDT. Tous ont connu une reconstitution hématopoïétique rapide, une expression pan-cellulaire soutenue et à haut niveau
More news about: CorrectSequence Therapeutics
Sep 07, 2026, 20:00 ET Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia.SHANGHAI, Sept. 8, 2026
More news about: CorrectSequence Therapeutics
Sep 07, 2026, 20:00 ET Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia.SHANGHAI, Sept. 7, 2026
More news about: CorrectSequence Therapeutics
Aug 25, 2026, 07:45 ET Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer
candidate, VAS-101 (Vasceptor®), targets a common inflammatory pain pathway across three distinct disease settings: sickle cell disease (SCD), chemotherapy-induced pain in cancer, and osteoarthritis (OA). Taken together, the company believes this body of work positions Vasceptor as a potential
More news about: Vascarta Inc.
Aug 24, 2026, 11:01 ET Researchers Find No Connection Between Pesticide Exposure and Social Difficulties Common in Autism
City.Other study co-investigators are Heather Volk, PhD, MPH, at the Johns Hopkins University in Baltimore; Apollo Kivumbi, MD, MPH, and Kristen Lyall, ScD, at Drexel University in Philadelphia; Kurunthachalam Kannan, PhD, and Zhongmin Li, PhD, in the New York State Department of Health; Allison Sherris,
More news about: NYU Grossman School of Medicine and NYU Langone Health
Aug 20, 2026, 13:49 ET Vascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease
Vascarta Inc., a clinical-stage biopharmaceutical company advancing transdermal curcuminoid therapeutics for pain, inflammation, and sickle cell disease (SCD), today outlined a proposed mechanistic framework connecting two recent findings on Vasceptor® (VAS-101): a newly published preclinical study demonstrating
More news about: Vascarta Inc.
Aug 19, 2026, 14:18 ET Vascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins
VAS-101 has the potential to become the new standard of care in the management of SCD.SCD is caused by a single point mutation in the beta hemoglobin gene leading to sickling of red blood cells. It is characterized by severe pain, inflammation,
More news about: Vascarta Inc.
Aug 17, 2026, 09:15 ET Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
androgen receptor blocker) with an SCD1 inhibitor blocks this lipid synthesis and desaturation, potentially leading to decreased cell viability, and delayed development of drug resistance.The data we present today, demonstrate that a combination of Aramchol (an SCD1 inhibitor) with enzalutamide resulted
More news about: Galmed Pharmaceuticals Ltd.
Aug 06, 2026, 16:05 ET Cryoport Reports Second Quarter 2026 Financial Results
two years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved gene therapy indicated for children as young as two years for both SCD and TDT. For the balance of 2026, we anticipate another
More news about: Cryoport, Inc.
Jul 28, 2026, 10:00 ET Children's Hospital Colorado Helps Shape National Standards for Neurodevelopmental and Neurocognitive Care in Sickle Cell Disease
how clinicians identify and manage developmental and cognitive challenges in individuals living with sickle cell disease (SCD) across the lifespan. Care for children and adults with SCD varies significantly depending on where they live and receive treatment, and this new guidance — partially informed by
More news about: Children's Hospital Colorado
Jul 28, 2026, 07:00 ET Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
The inhibition of stearoyl-CoA desaturase 1 (SCD1) is a novel disease approach in Parkinson's Disease, that targets the cause of neurodegeneration. Growing evidence identifies SCD1 as a central regulator of lipid metabolism that contributes to α-synuclein aggregation,
More news about: Galmed Pharmaceuticals Ltd.
Jul 16, 2026, 07:30 ET Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
content:https://www.prnewswire.com/news-releases/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-targeted-formulation-of-its-scd1-inhibitor-aramchol-302827443.htmlSOURCE
More news about: Galmed Pharmaceuticals Ltd.
Jun 25, 2026, 14:00 ET Epigenetic Clocks vs. VO₂ Max: How Do You Actually Prove a Longevity Treatment Is Working? Healthi Life Analysis Explores Which Biomarkers Hold Up Under Placebo-Controlled Scrutiny
reduction of 3.1 years. All three results were statistically significant at p ≤ 0.01 after adjustment for sex, BMI, hsCRP, and sCD163.This trial is notable because of what it controls for. Earlier observational data on peptides and aging biomarkers could not rule out that epigenetic
More news about: Healthi Life
Jun 24, 2026, 14:50 ET Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
Black individuals in the United States. SCD associated complications include anemia, acute and chronic pain, infections, pneumonia and acute chest syndrome, stroke, and kidney, liver, and heart disease.Current estimates indicate there are >165,000 cases of SCD in the USA & 45,000 in European
More news about: Vascarta Inc.
Jun 24, 2026, 08:30 ET From Data to Evidence: A Framework for RWD Study Design & Causal Inference, Upcoming Webinar Hosted by Xtalks
TriNetX; and Miguel Hernán, MD, PhD, ScD, Director of CAUSALab, Professor of Biostatistics and Epidemiology, Harvard, for the live webinar on Thursday, July 16, 2026, at 11am EDT (5pm CEST/EU-Central).For
More news about: Xtalks
Jun 03, 2026, 09:16 ET Hochpräzise Basen-Editierungstherapie zeigt dauerhafte VOC-freie Wirksamkeit und günstige Sicherheit bei Sichelzellanämie
Gebiet der transformer Base Editing (tBE)-Technologie für schwere Krankheiten leistet, gab bekannt, dass der erste Patient mit Sichelzellkrankheit (SCD), der in China mit seiner hochpräzisen Base-Editing-Therapie CS-206 behandelt wird, seit mehr als 15 Monaten nach der Transplantation frei von vaso-okklusiven
More news about: CorrectSequence Therapeutics
Jun 03, 2026, 09:16 ET Terapia de edição de bases de alta precisão demonstra eficácia duradoura sem VOCs e perfil de segurança favorável na doença falciforme
estágio clínico pioneira na tecnologia de transformer Base Editing (tBE) para doenças graves, anunciou que o primeiro paciente com doença falciforme (SCD) sendo tratado na China com sua terapia de edição de bases de alta precisão CS-206 não sofreu crises vaso-oclusivas (VOCs) por mais de 15 meses após
More news about: CorrectSequence Therapeutics
Jun 03, 2026, 09:15 ET La terapia de edición de bases de alta precisión demuestra una eficacia duradera sin VOC y una seguridad favorable en la enfermedad de células falciformes
desarrollando la tecnología de transformer Base Editing (tBE) para enfermedades graves, anunció que el primer paciente con enfermedad de células falciformes (SCD) tratado en China con su terapia de edición genética de alta precisión CS-206 no ha presentado crisis vaso-oclusivas (VOC) durante más de 15 meses después
More news about: CorrectSequence Therapeutics
Jun 03, 2026, 06:23 ET La terapia de edición de bases de alta precisión demuestra una eficacia duradera sin VOC
pionera en la tecnología de transformer Base Editing (tBE) para enfermedades graves, ha anunciado hoy que la primera paciente con anemia falciforme (SCD) tratada en China con su terapia de edición de bases de alta precisión CS-206 ha permanecido libre de crisis vasooclusivas (VOC) durante más de 15 meses
More news about: CorrectSequence Therapeutics
Jun 02, 2026, 13:00 ET K2 Medical Research Opens Boston Area Site in Foxboro, MA - Expanding Access to Clinical Trials and Innovative Treatments
Southern New England. The site's leadership team includes Principal Investigators Daniel Sacchetti, DO, FAAN, and John Stoukides, MD, SCD, RPH, physicians with deep roots in the region's medical community, and William Menard, Managing Partner.
More news about: K2 Medical Research
Jun 02, 2026, 07:30 ET Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
liver, cardiometabolic, and GI oncology diseases, today announced results from a preclinical study evaluating a combination of Aramchol Meglumine, an SCD1 inhibitor, and a selective PPARα agonist. The study identified a previously unrecognized metabolic pathway involved in the progression of cardiac fibrosis
More news about: Galmed Pharmaceuticals Ltd.
Jun 02, 2026, 00:54 ET High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases, announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15
More news about: CorrectSequence Therapeutics
Jun 02, 2026, 00:50 ET High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases, announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15
More news about: CorrectSequence Therapeutics